KIRKLAND, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Conor Hanley as an independent director to its board, effective June 4, 2025.
“I am delighted to welcome Conor to our board of directors,” said Brian Webster, President and CEO of Kestra Medical Technologies. “He brings deep expertise in medical technology and cardiac care and will serve as an invaluable strategic resource as we grow and expand the reach of the ASSURE® system.”
Mr. Hanley is a chartered director and currently serves as CEO of FIRE1, a venture-backed connected medical device solutions company dedicated to improving outcomes for people with heart failure. He previously held senior management roles at ResMed, including leading the cardiology business unit and chronic disease management solutions globally. Prior to ResMed, Mr. Hanley was co-founder and CEO of BiancaMed, a medical device company that was acquired by ResMed. Mr. Hanley earned a PhD in chemical engineering from the University of Pennsylvania and an MBA from INSEAD. His previous board experience includes Enterprise Ireland and chair of APC Ltd. and the Irish MedTech association.
“I am honored to join the Kestra board of directors,” said Mr. Hanley. “Kestra is driving much-needed innovation in the wearable cardioverter defibrillator market, and I look forward to collaborating with the management team as the company scales its operations and delivers on its commitments to patients and prescribers.”
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.
September 25, 2025 September 17, 2025 July 15, 2025 April 29, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load